Exploiting the Anti-HIV-1 activity of acyclovir: Suppression of primary and drug-resistant HIV isolates and potentiation of the activity by Ribavirin by Vanpouille, Christopher et al.
  Published Ahead of Print 6 February 2012. 
10.1128/AAC.05986-11. 
2012, 56(5):2604. DOI:Antimicrob. Agents Chemother. 
McGuigan, Jan Balzarini and Leonid Margolis
Raymond F. Schinazi, Marco Derudas, Christopher
Jean-Charles Grivel, Arshi Munawwar, Melanie Merbah, 
Christophe Vanpouille, Andrea Lisco, Andrea Introini,
 
Potentiation of the Activity by Ribavirin
Drug-Resistant HIV Isolates and
Acyclovir: Suppression of Primary and 
Exploiting the Anti-HIV-1 Activity of
http://aac.asm.org/content/56/5/2604
Updated information and services can be found at: 
These include:
REFERENCES
http://aac.asm.org/content/56/5/2604#ref-list-1at: 
This article cites 44 articles, 18 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 February 24, 2014 by Cardiff Univ
http://aac.asm
.org/
D
ow
nloaded from
 
 o
n
 February 24, 2014 by Cardiff Univ
http://aac.asm
.org/
D
ow
nloaded from
 
Exploiting the Anti-HIV-1 Activity of Acyclovir: Suppression of
Primary and Drug-Resistant HIV Isolates and Potentiation of the
Activity by Ribavirin
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Eunice Kennedy Shriver National Institute of Child Health and Human Development, Program of Physical Biology, National Institutes of Health, Bethesda, Maryland, USAa;
Clinical Microbiology Division, Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi, Indiab; Center for AIDS Research, Department of
Pediatrics, Emory University School of Medicine, Veterans Affairs Medical Center, Decatur, Georgia, USAc; Welsh School of Pharmacy, Cardiff University, Cardiff, United
Kingdomd; and Rega Institute for Medical Research, Katholieke Universiteit, Leuven, Belgiume
Multiple clinical trials have demonstrated that herpes simplex virus 2 (HSV-2) suppressive therapy using acyclovir (ACV) or va-
lacyclovir in HIV-1/HSV-2-infected persons increased the patient’s survival and decreased the HIV-1 load. It has been shown
that the incorporation of ACV-monophosphate into the nascent DNA chain instead of dGMP results in the termination of viral
DNA elongation and directly inhibits laboratory strains of HIV-1. We evaluated here the anti-HIV activity of ACV against pri-
mary HIV-1 isolates of different clades and coreceptor specificity and against viral isolates resistant to currently used drugs, in-
cluding zidovudine, lamivudine, nevirapine, a combination of nucleoside reverse transcriptase inhibitors (NRTIs), a fusion in-
hibitor, and two protease inhibitors. We found that, at clinically relevant concentrations, ACV inhibits the replication of these
isolates in human tissues infected ex vivo. Moreover, addition of ribavirin, an antiviral capable of depleting the pool of intracel-
lular dGTP, potentiated the ACV-mediated HIV-1 suppression. These data warrant further clinical investigations of the benefits
of using inexpensive and safe ACV alone or in combination with other drugs against HIV-1, especially to complement or delay
highly active antiretroviral therapy (HAART) initiation in low-resource settings.
Compelling clinical evidence has demonstrated that the treat-ment of HIV-1-infected persons with acyclovir (ACV) or its
prodrug valacyclovir (vACV) reduces HIV-1 load and delays
HIV-1 disease progression (20). In particular, ACV/vACV treat-
ments are associated with a reduction of HIV-1 load in plasma,
semen, cervico-vaginal secretions, and rectal swabs (3, 9, 11, 20,
27, 45, 46) and in plasma during pregnancy (10). Also, several
clinical studies, as well as two meta-analyses of a total of 15 ran-
domized clinical studies, demonstrate that ACV/vACV treatment
delays progression to AIDS and prolongs the patient’s survival
(14, 22).
Understanding the mechanisms of ACV/vACV anti-HIV-1 ac-
tivity is crucial to assessing its potential clinical use. It is hypoth-
esized that ACV/vACV, an acyclic guanosine analogue, reduces
HIV-1 load indirectly by suppressing HSV-2-mediated inflamma-
tion (41). However, we and others have shown that upon phos-
phorylation by kinases expressed by coinfecting human herpesvi-
ruses (HHVs) (including, but not limited to, herpes simplex virus
2 [HSV-2]), ACV directly inhibits HIV-1 reverse transcriptase
(RT) (21, 25). These findings suggest that the anti-HIV activity of
ACV may not be restricted to subjects coinfected with HSV-2, as
other HHVs or yet unknown host enzymes (24) are also able to
phosphorylate ACV. In consideration of its wide availability,
safety, and low cost compared to other antiretroviral agents, ACV/
vACV could be utilized to complement or delay highly active an-
tiretroviral therapy (HAART) initiation in low-resource settings.
Here, we further investigate the antiviral activity of ACV
against HIV-1 in experiments designed to mimic clinically rele-
vant situations: (i) we evaluated its anti-HIV-1 activity not only
against laboratory HIV-1 strains but also against primary HIV-1
clinical isolates of different subtypes and against multidrug-resis-
tant variants; (ii) we evaluated the effect of ribavirin, a drug that is
used against hepatitis C virus (HCV), on the anti-HIV-1 activity of
ACV, since ribavirin is known to deplete the pool of the intracel-
lular counterpart of ACV-triphosphate (ACV-TP), dGTP.
METHODS AND MATERIALS
Cultures and viral stocks. Tonsillar tissues obtained from the Children’s
National Medical Center (Washington, DC), in accordance with an IRB-
approved protocol, were dissected and cultured as described elsewhere
(13). The MT-4 T-cell line was obtained from ATCC and maintained in
RPMI with 10% fetal calf serum (FCS). The analysis of tonsillar tissue
samples from 38 different donors showed that all of them contain HHVs
of different types (21).
Virus stocks. HIV-1LAI.04 viral stocks were obtained from the Rush
University Virology Quality Assurance Laboratory (Chicago, IL). Primary
isolate viruses (HIV-196USNG31, HIV-197USNG30, HIV-196USNN20, and
HIV-1ME1), multi-nucleoside reverse transcriptase inhibitor (NRTI)-re-
sistant viruses (HIV-17324-4, HIV-110076-4, HIV-16463-13, HIV-17303-3,
HIV-11617-1, and HIV-135764-2), nevirapine-resistant virus (HIV-1N119),
fusion inhibitor-resistant virus (HIV-1pNL4-3 gp41(36G)/V38A/N42D), and
protease inhibitor-resistant virus (HIV-1L10R/M46I/L63P/V82T/I84V and
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HIV-1M46I/L63P/V82T/I84V) were obtained through the NIH AIDS Research
and Reference Reagent Program (7, 16, 31, 32, 36). Lamivudine-resistant
HIV-1 isolates (carrying the M184V mutation in HIV-1 RT) and zidovu-
dine (AZT)-resistant strain 4X (AZT.4X) (carrying D67N, K70R, T215Y,
and K219Q mutations in HIV-1 RT) were provided by Raymond Schinazi
(1, 18).
Viral infections and drug treatment. Tonsillar tissue blocks were in-
oculated with each HIV-1 isolate and treated for the entire culture period
with ACV pharmaceutical formulations (Bedford Laboratories, Bedford,
OH) and/or ribavirin (Sigma-Aldrich, St. Louis, MO) at the indicated
concentrations. Drugs were present during the entire period of culture
and were replenished with each medium change (every 3 days). The po-
tentiation effect of ribavirin on the anti-HIV-1 activity of ACV-ProTides
was investigated in MT-4 cell cultures: briefly, 105 MT-4 cells infected
with HIV-1LAI.04 were cultured for 4 days in the presence of ribavirin at
concentrations ranging from 1 to 20 M and in the presence of ACV-
ProTide at concentrations ranging from 0.01 to 50 M. HIV replication
was evaluated by p24gag antigen release in culture medium as previously
described (21).
Statistical analysis. For each experiment, we compared virus-infected
and control tissues obtained from an individual donor in replicates of 27
tissue blocks for each data point. Experiments were repeated with tissues
of n donors, where n is specified throughout the text. To average the
results of different experiments and to analyze them statistically, we nor-
malized the data as percentages of untreated controls and determined the
means  standard errors of the means (SEM). The data presented in
Tables 1 and 2 are means standard deviations (SD). We used Student’s
unpaired t test to evaluate the significance of the differences between the
inhibition of each virus (primary isolates AZT.4X and M184V; multi-
NRTI-resistant, nevirapine-resistant, protease inhibitor-resistant, and
fusion inhibitor-resistant HIV-1) and our laboratory reference strain
HIV-1LAI.04.
RESULTS
ACV suppresses replication of primary HIV-1 isolates. Previ-
ously, we reported that ACV suppresses replication of four labo-
ratory HIV-1 strains, CXCR4-tropic LAI.04 (HIV-1LAI.04), CCR5-
tropic BaL, SF162, and AD8, in ex vivo infected human lymphoid
tissues (21). Here, we evaluated the susceptibility of four primary
isolates to ACV: HIV-196USNG31 and HIV-197USNG30 of clade C,
HIV-196USNN20 of clade A, and HIV-1ME1 of clade B. Isolate HIV-
196USNG31 uses CCR3, CCR5, and CXCR4; HIV-196USNN20 has a
broad coreceptor utilization, including CCR2B, CCR3, CCR4,
CCR5, CXCR4, Bob, and Bonzo; HIV-197USNG30 and HIV-1ME1
are exclusively CCR5 tropic.
Human lymphoid tissues were inoculated with each of these
TABLE 1 Inhibition of HIV-1 replication by ACV in tonsillar tissues ex vivoa
Strainb
HIV replicationc % Inhibition by ACVd
Untreated control
ACV
3 M 30 M3 M 30 M
Primary HIV-1 isolates
HIV-1LAI.04 13,052 (4,508–19,484) 7,714 (1,487–12,305) 749 (267–3,238) 47 17 83 15
HIV-196USNG31 4,455 (566–27,716) 3,836 (608–16,167) 871 (175–2,031) 20 18* 71 13
HIV-197USNG30 14,050 (4,373–71,055) 12,926 (3,568–46,592) 7,438 (1,404–24,983) 54 22 82 21
HIV-196USNN20 5,365 (3,351–10,700) 4,832 (2,017–10,142) 2,059 (596–5,403) 34 26 68 18
HIV-1ME1 4,462 (2,166–6,919) 2,263 (1,137–3,287) 261 (215–336) 53 11 91 6
AZT-resistant variant HIV-1AZT.4X 18,006 (15,618–30,906) 10,325 (9,033–15,529) 6,946 (6,573–9,967) 57 3 74 7
Lamivudine-resistant variant HIV-1M184V 33,750 (27,305–44,612) 37,165 (28,921–43,976) 10,103 (8,118–14,408) 14 18* 65 27
Multi-NRTI-resistant variants
HIV-17324–4 1,904 (752–4,139) 791 (203–1,782) 67 (0–598) 58 17 92 12
HIV-110076–4 4,664 (513–11,393) 1,415 (360–13,650) 29 (13–627) 57 42 90 15
HIV-16463–13 793 (577–16,866) 782 (550–17,295) 33 (17–3,359) 4 7* 90 10
HIV-17303–3 3,389 (1,940–10,550) 2,524 (867–7,047) 1,054 (253–4,206) 31 26 73 29
HIV-11617–1 12,559 (1,693–34,307) 9,125 (2104–23,525) 1,861 (216–4,273) 18 15* 88 13
HIV-135764–2 933 (818–9,311) 295 (211–3,349) 98 (91–302) 55 31 91 11
Nevirapine-resistant variant HIV-1N119 52,832 (18,027–139,405) 8,019 (6,935–9,104) 16,599 (6,152–29,579) 55 51 84 12
Fusion inhibitor-resistant variant
HIV-1
pNL4–3 gp41(36G)/V38A/N42D
1,043 (778–2,881) 619 (600–1,174) 48 (44–56) 35 32 94 6
Protease inhibitor-resistant HIV-1 variants
HIV-1L10R/M46I/L63P/V82T/I84V 23,863 (18,986–31,508) 12,590 (11,524–15,546) 902 (614–1,148) 40 37 96 2
HIV-1M46I/L63P/V82T/I84V 4,410 (287–10,834) 3,685 (55–8,507) 348 (24–1,095) 47 31 86 11
a For each isolate and each experimental condition, 27 tonsillar tissue blocks were inoculated with each HIV-1 isolate from a multi-NRTI-resistant HIV-1 panel and treated for 12
days with 3 or 30 M ACV.
b Multi-NRTI-resistant clone HIV-17324-4 carried the mutations 41L, 70R, 215F, and 219E on its reverse transcriptase. HIV-110076-4 carried mutations 41L, 215Y, and 184V. HIV-
16463-13 carried the mutations 41L, 67N, 210W, 215Y, 184V, and 118I. HIV-17303-3 carried the mutations 41L, 67N, 201W, 215Y, 69D, 44D, and 118I. HIV-11617-1 carried the
mutations G70, 184V, 69K, 75I, 77L, 116Y, and 151 M. HIV-135764-2 carried the mutations 75I, 77L, 118Y, and 151 M (11).
c For each viral isolate, the median cumulative p24gag release (pg/ml) and interquartile range (25 to 75%) in culture supernatant of infected tissues were calculated from n
independent experiments. n 3 to 7 for all conditions (except HIV-1AZT.4X replication in the untreated control and HIV-1N119 in the 3 M ACV-treated condition, where n 2).
d Percentage (mean SD) of inhibition of HIV replication by 3 or 30 M ACV is defined as [1(RACV/RCtl)] 100, where RACV and RCtl are the amounts of p24 accumulated in
the medium over the 12-day culture period in ACV-treated cultures and in donor-matched untreated cultures, respectively. *, P 0.05 (inhibition of replication of HIV variants
compared to reference strain HIV-1LAI.04).
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isolates and then treated for the entire culture period with ACV at
3 or 30M. These concentrations were chosen on the basis of our
previous work with this compound (21). The median cumulative
release of p24gag in the culture supernatants of tissues infected
with each primary HIV-1 isolate with or without ACV is presented
in Table 1. ACV suppresses replication of primary isolate HIV-
197USNG30, HIV-196USNN20, and HIV-1ME1, and this suppression
was not significantly different from that of laboratory isolate HIV-
1LAI.04 at both 3 and 30M ACV (P 0.05) (Fig. 1). At 3M, the
inhibition of HIV-196USNG31 replication was lower than that of
the laboratory strain HIV-1LAI.04 (P 0.03). However, at 30 M,
the ACV inhibitory activity was not statistically different for the
two viruses (P 0.05).
In summary, we found that primary isolates from clade A and
B were inhibited by ACV as efficiently as the laboratory isolate
HIV-1LAI.04. However, one of the two clade C HIV-1 subtypes
tested had lower susceptibility to ACV compared to HIV-1LAI.04.
ACV suppresses NRTI-resistant HIV-1 isolates. We assessed
the ACV susceptibility of HIV-1 variants that are resistant to one
or more licensed NRTIs. First, we investigated the ACV anti-HIV
activity against the AZT-resistant isolate AZT.4X (characterized
by the D67N, K70R, T215Y, and K219Q mutations in RT) in ex
vivo lymphoid tissues. ACV at concentrations of 3 and 30 M
inhibited AZT.4X replication by 57.2%  2.3% and 73.7% 
4.0%, respectively. No statistical difference between the inhibition
of AZT.4X and the inhibition of the laboratory strain HIV-1LAI.04
was observed (P 0.05) (Table 1).
Similar experiments were performed with a lamivudine-resis-
TABLE 2 Potentiation of the ACV anti-HIV-1 activity by ribavirin in
human tonsillar tissuesa
Condition
ACV
concn
(M)
HIV-1 replication
[median p24gag (IQR)]
b % inhibitionc
Ribavirin (10 M)
0 7,379 (4,135–10,737) NA
0.3 5,020 (3,220–8,837) 18.3 16.8
3 2,284 (1,426–4,497) 65.9 17.0 *
10 1,327 (1,098–1,807) 91.8 7.5**
No ribavirin 0 8,228 (3,714–12,357) NA
0.3 8,528 (5,844–12,112) 6.1 11.7
3 5,869 (3,554–8,257) 41.3 25.2
10 3,234 (1,554–5,489) 65.2 17.6
a For each condition, 27 tonsillar tissue blocks from each of n donors were inoculated
with X4LAI.04 and treated for a 12-day period with 1, 3, or 10 M ACV in the absence or
presence of 10 M ribavirin.
b Median cumulative p24gag release (pg/ml) in culture supernatant of infected tissues.
n 10 for all data points except for 10 M ACV, where n 6. IQR, interquartile
range.
c Percentage (mean SD) of inhibition of HIV replication is defined as [1(RACV/
RCtl)] 100, where RACV and RCtl are the amounts of p24gag accumulated in the
medium over a 12-day culture period in ACV-treated cultures and in donor-matched
untreated ACV cultures, respectively. *, P value of 0.05 for HIV-1LAI.04 inhibition in
the absence versus in the presence of 10 M ribavirin at 3 M ACV. **, P value of
 0.05 for HIV-1LAI.04 inhibition in the absence versus in the presence of 10 M
ribavirin at 30 M ACV. NA, not available.
FIG 1 Inhibition of HIV-1 replication by ACV in human lymphoid tissues. Tissue blocks (27 from each donor) were infected with HIV-197USNG31, HIV-
196USNN20, HIV-197USNG30, or HIV-1ME1 and treated with 3 or 30M ACV. Replication of HIV-1 was evaluated by p24gag core antigen release in pooled medium
bathing 27 tissue blocks using a bead-based assay. Each point represents the measurement of medium pooled from three wells, each of which contained nine
tissue blocks. The anti-HIV activity of ACV was evaluated by comparing viral replication in drug-treated tissues with that in untreated donor-matched control
tissues. The graph represents the typical replication kinetics of 4 to 6 experiments performed with tissues from different donors. For average replication values,
see Table 1.
Vanpouille et al.
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tant HIV isolate carrying the M184V mutation in RT (M184V
HIV-1LAI.04). The replication of M184V virus in tissues treated
with 3 M ACV was suppressed by 13.6%  8.9%, while the
replication of the parental HIV-1LAI.04 was suppressed by 47.0%
7.0% (P  0.02). At 30 M ACV, no difference was observed
between M184V HIV-1LAI.04 and HIV-1LAI.04 (64.9%  15.6%
and 83.0% 6.0%, respectively [P 0.05]) (Table 1).
Because drug resistance may often manifest as multidrug resis-
tance, we tested the ACV susceptibility of a panel of six prototyp-
ical multi-NRTI-resistant HIV-1 molecular clones (HIV7324 – 4,
HIV10076 – 4, HIV6463–13, HIV7303–3, HIV1617–1, and HIV35764 –2)
(Fig. 2). Each of the six molecular clones carries several prototyp-
ical mutations that confer resistance to at least two of the following
NRTIs: abacavir, zidovudine, stavudine, zalcitabine, didanosine,
tenofovir, and lamivudine (12).
HIV-1 suppression with 3 M ACV is summarized in Table 1.
The statistical analysis shows that at 3 M, ACV inhibited the
multi-NRTI-resistant HIV7324 – 4, HIV10076 – 4, HIV7303–3, and
HIV35764 –2 as efficiently as HIV-1LAI.04 (P  0.05). In contrast,
replications of HIV6463–13 and HIV1617–1 were significantly less
inhibited than that of HIV-1LAI.04 (P  0.003 and P  0.02, re-
spectively). At 30M, all of the multi-NRTI-resistant viruses were
suppressed similarly to HIV-1LAI.04 (P 0.05) (Fig. 2).
To evaluate whether HIV-1 RT single mutations could inter-
fere with ACV anti-HIV-1 activity, we compared the susceptibil-
ities of the singly RT-mutated viruses HIV-1K65R, HIV-1L74V,
HIV-1V75I, and HIV-1Q151M to their HIV-1LAI.04 control at two
concentrations of ACV (3 and 30M). In five independent exper-
iments performed with tissues from five different donors, we
found that all singly mutated viruses were susceptible to ACV at
rates equal to that of the HIV-1LAI.04 control (P  0.05), except
HIV-1K65R, which at 30 M ACV exhibited a 2-fold-reduced
susceptibility compared to that of HIV-1LAI.04 (48.8%  7.7%
inhibition versus 80.9% 6.6% [P 0.007]).
ACV suppresses NNRTI-resistant HIV-1 isolates. Further-
more, we evaluated the ACV-mediated suppression of HIV-1N119
in human lymphoid tissue ex vivo. HIV-1N119 has the RT mutation
Y181C, which confers resistance to nevirapine, as well as to related
nonnucleoside reverse transcriptase inhibitors (NNRTIs). HIV-
1N119 replication was suppressed by 54.9% 35.9% and by 83.9%
 6.1% at 3 and 30 M ACV, respectively, rates similar to that of
HIV-1LAI.04 (P 0.05) (21) (Table 1).
ACV suppresses HIV-1 isolates resistant to protease and fu-
sion inhibitors. We tested the ACV susceptibility of HIV-1 isolates
resistant to a fusion inhibitor (HIV-1pNL4-3 gp41(36G)/V38A/N42D) or
two protease inhibitors (HIV-1L10R/M46I/L63P/V82T/I84V and HIV-
1M46I/L63P/V82T/I84V). HIV-1pNL4-3 gp41(36G)/V38A/N42D is a recombi-
nant virus that contains one or more amino acid substitutions in
gp41 which confer resistance to enfuvirtide (T-20). Both HIV-
1L10R/M46I/L63P/V82T/I84V and HIV-1M46I/L63P/V82T/I84V are resistant
to the structurally diverse protease inhibitors MK-639, XM323,
A-80897, Ro31-8959, VX-478, and SC-52151 (7).
We did not observe any difference in ACV-mediated inhi-
bition of HIV-1LAI.04, HIV-1pNL4-3 gp41 (36G) V38A, N42D, HIV-
1L10R/M46I/L63P/V82T/I84V, and HIV-1M46I/L63P/V82T/I84V at either 3 or
30 M ACV (P 0.05, Table 1). Thus, both fusion and protease
inhibitor-resistant HIV-1 variants tested here retained suscepti-
bility to ACV at a level similar to that of the wild-type HIV-1
(HIV-1LAI.04).
Ribavirin potentiates the anti-HIV-1 activity of ACV and of
ACV prodrug derivatives. We investigated in T-cell lines and in
ex vivo human lymphoid tissues whether ribavirin, an antiviral
compound known to deplete the intracellular dGTP pool, poten-
tiates the anti-HIV activity of a dGTP antagonist, ACV. Control
experiments did not show a statistically significant difference be-
tween the cumulative p24gag production in HIV-1LAI.04-infected
tissues treated and that in tissues not treated with ribavirin (P 
0.05) (Table 2).
Next, in human lymphoid tissue ex vivo, we evaluated the sus-
ceptibility of HIV-1 replication to the combination of ribavirin
and ACV. Without ribavirin, 3 M ACV suppressed HIV-1LAI.04
replication by 41.3%  8.0%, while in the presence of ribavirin,
HIV-1LAI.04 replication was inhibited by 65.9%  5.4% (P 
0.008). Similarly, in the absence of ribavirin, 10 M ACV sup-
pressed HIV-1LAI.04 replication by 65.2%  5.6%, while in the
presence of ribavirin, HIV-1LAI.04 replication was inhibited by
91.8% 2.4% (P 0.025). Also, 10M ribavirin potentiated the
anti-HIV-1 activity of 0.3M ACV (18.3% 5.3% versus 6.1%
3.7% inhibition in the absence and presence of ribavirin, respec-
tively) (Fig. 3). However, this potentiation did not reach statistical
significance (P 0.05).
Also, we evaluated the effect of ribavirin on the suppressive
activity of ACV in MT-4 cells. Unlike human tissues, which con-
tain various HHVs that activate (phosphorylate) ACV into ACV-
MP, MT-4 cells are HHV free; therefore, in these experiments we
used ACV-ProTides, which are lipophilic phosphorylated ACV
prodrug derivatives (42).
For each experimental condition, 105 MT-4 cells infected with
HIV-1LAI.04 were treated with ACV ProTides Cf2648 or Cf2681 at
FIG 2 Inhibition of replication of multidrug-resistant HIV-1 clones by ACV
in human lymphoid tissues. Donor-matched sets of tissue (27 blocks for each
experimental condition from each of three to seven donors) were incubated
with ACV (3 or 30M) for 12 days or used as untreated controls. Some of these
sets were infected with multi-NRTI-resistant clones HIV-17324 – 4, HIV-
110076 – 4, HIV-17303–3, HIV-16463–13, HIV-11617–1, and HIV-135764 –2 or with
the laboratory strain HIV-1LAI.04. Replication of HIV-1 was evaluated by
p24gag core antigen release in pooled medium bathing 27 tissue blocks using a
bead-based assay. The anti-HIV activity of ACV, as a percentage, was evaluated
by comparing viral replication in drug-treated tissues with that in untreated
donor-matched control tissues. Presented are means SEM of HIV-1 inhibi-
tion in 27 human tissue blocks from each of three to seven donors, relative to
results for matched untreated tissues (n 3 for HIV-17324 – 4 and HIV-16463–13;
n 4 for HIV-11617–1; n 7 for HIV-110076 – 4, HIV-17303–3, HIV-135764 –2, and
HIV-1LAI.04).
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concentrations varying from 0.2 to 50 M in the absence of riba-
virin. When cells were treated with ribavirin at concentrations
ranging from 1 to 20 M, ACV ProTides Cf2648 or Cf2681 was
added at concentrations varying from 0.01 to 20 M. For both
ProTides, ribavirin markedly decreased the 50% effective concen-
tration (EC50): ribavirin decreased the EC50 from 1.3 to 0.018M
for Cf2681 and from 9 to 1.8 M for Cf2648 (Fig. 4).
DISCUSSION
The growing evidence of the important role played by sexually
transmitted infections in general and by HSV-2 in particular in
HIV transmission and pathogenesis has led to the development of
new anti-HIV-1 strategies aimed at suppressing coinfecting vi-
ruses. Highly specific and potent anti-herpetic drugs were devel-
oped in the mid-1970s, making it possible to test these strategies in
randomized clinical trials of HSV-2 suppressive therapy using
ACV/vACV. These trials consistently demonstrated that such
therapy resulted in increased survival and a decrease in HIV-1
load by 0.3 to 0.5 log10 in plasma, semen, cervico-vaginal secre-
tions, and rectal swabs (3, 9, 11, 20, 27, 45, 46) and by 0.5 log10 in
plasma during pregnancy (10). Although this effect is relatively
small compared to that produced by the current potent anti-HIV
cocktails, it is important to remember that the effect achieved by
ACV monotherapy is similar to the monotherapy effect of zidovu-
dine, which is one of the most efficient components of HAART
(17). Moreover, two studies have recently reported that HSV-2
suppressive therapy using ACV (400 mg twice daily [b.i.d.]) de-
layed HIV-1 disease progression by 16% (20) and 27% (30). This
delay may seem modest, but given HSV-2 seroprevalence rates as
high as 90% in HIV-infected individuals in sub-Saharan Africa
and the limited resources in parts of this region, low-cost inter-
ventions with well-tolerated drugs which can slow disease pro-
gression are an appealing strategy to delay initiation of HAART or
the onset of AIDS in coinfected individuals (6, 38). Deciphering
the mechanisms by which ACV suppresses HIV-1 is therefore im-
portant both for basic virology and for optimization of anti-
HIV-1 therapeutic strategies.
Earlier, we and others (21, 25) showed that ACV, upon meta-
bolic activation, is a direct inhibitor of HIV-1. In particular, we
found that human tissues, including the tonsil tissues used in these
studies, carry HHVs (not necessarily HSV-2) (21). Furthermore,
when these tissues are infected ex vivo with HIV-1, ACV is phos-
phorylated by HHV-encoded kinases (and/or possibly by yet un-
defined host kinases) (24) and acts as an NRTI, directly inhibiting
HIV-1 RT (21).
In the studies referenced above, the anti-HIV-1 activity of ACV
was tested for well-defined laboratory-adapted strains of HIV-1,
which may be different from primary isolates in several important
aspects. In the current work, we tested the anti-HIV activity of
ACV against primary isolates and drug-resistant isolates that com-
monly emerge in treated patients. We performed these tests in an
ex vivo system of human tissues that reflects many in vivo tissue
features.
We found that ACV inhibited all primary and multidrug-resis-
tant HIV-1 variants tested. Moreover, the understanding of the
molecular mechanism of ACV-mediated HIV-1 suppression al-
lowed us to potentiate ACV suppressive activity by adding ribavi-
rin, a known antiviral used in HCV treatment, which is capable of
depleting the pool of intracellular dGTP (8).
We first tested the susceptibility of four clinical HIV-1 isolates
to two concentrations of ACV, 3 and 30 M, in ex vivo lymphoid
tissue. These concentrations of ACV were chosen because they are
in the range of those achieved in patients treated with oral ACV/
vACV (23, 34) and they have been reported to inhibit the replica-
tion of HIV-1 laboratory isolates by approximately 50 and 90%,
respectively (21). ACV suppressed the replication of all tested
HIV-1 primary isolates, including two of clade C, which is preva-
lent in Southern and East Africa and India and is responsible for
nearly half of all HIV infections worldwide, one of clade A, mainly
present in Western/Central Africa and Russia, and one of clade B,
commonly found in Europe, the Americas, and Australia. Also,
the inhibition was irrespective of HIV-1 coreceptor specificity
(CCR5, CXCR4, CCR3, CCR2B, Bob, Bonzo). In general, there
FIG 4 Potentiation of the anti-HIV-1 activity of ACV ProTides by ribavirin in
MT-4 cell culture. MT-4 cells (105) infected with HIV-1LAI.04 were cultured for
4 days in the presence of ribavirin at concentrations ranging from 1 to 20 M
and ACV ProTides at concentrations ranging from 0.01 to 50 M. HIV repli-
cation was evaluated by p24gag antigen release in culture medium at the end of
the experiment using a bead-based assay. EC50s were calculated in an experi-
ment in which two ACV ProTides (Cf 2648 and Cf2681) were tested against
HIV-1LAI.04 as a function of different ribavirin concentrations.
FIG 3 Potentiation of the anti-HIV-1 activity of ACV by ribavirin in human
lymphoid tissue. Donor-matched tissue blocks (27 blocks from each donor)
were inoculated with HIV-1LAI.04 and treated with ACV (0.3, 3, or 10 M) in
the absence or presence of 10 M ribavirin. Replication of HIV-1 was evalu-
ated by p24gag core antigen release in pooled medium bathing 27 tissue blocks
using a bead-based assay. The percentage of HIV-1 inhibition was evaluated by
comparing viral replication in drug-treated tissues with that in untreated do-
nor-matched control tissues. Presented are means  SEM of HIV-1LAI.04 in-
hibition in 27 human tissue blocks from each of 6 to 10 donors, relative to
results for matched untreated tissues (n 6 for experiments performed with
0.3 M ACV; n 10 for experiments performed with 3 or 10 M ACV). An
asterisk denotes a statistically significant difference (P 0.05) in HIV-1LAI.04
inhibition between untreated and ribavirin-treated tissues.
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was no difference in suppression of viral replication in ex vivo
tonsillar tissues between clinical HIV-1 isolates and laboratory
strains, although one of the two clade C isolates (HIV-196USNG31)
was not as susceptible to the low concentration of ACV as the
laboratory isolate HIV-1LAI.04.
This result should be taken into consideration in the interpre-
tation of the current or recently completed clinical trials on the
anti-HIV use of ACV. In fact, although average delays of 16% and
27% of disease progression were observed (20, 30), variations in
the response to ACV, which might be explained by differences in
susceptibilities of particular HIV-1 isolates, especially to low-dose
ACV (i.e., 400 mg b.i.d.), were noted. In this regard, the higher
doses of ACV in two ongoing clinical trials (43; NCT01059084
[http://clinicaltrials.gov/ct2/show/NCT01059084]) (vACV, 500
mg b.i.d. or 1,000 mg thrice daily) may reduce the variability stem-
ming from the intrinsic differences in susceptibility of HIV-1 RT
of different isolates, as observed in our experiments in ex vivo
tissues treated with a higher concentration of ACV (30 M). Fur-
thermore, it has been recently reported that, among HIV-1/HSV-
2-coinfected persons, vACV suppressive therapy results in greater
reduction in plasma HIV-1 levels than standard-dose ACV sup-
pression (26).
For the future use of ACV or its derivatives in anti-HIV-1 ther-
apy, it is important that ACV remains active against common
drug-resistant HIV-1 variants that evolve in the course of regular
anti-HIV therapy. Indeed, in the United States, up to 50% of pa-
tients receiving antiretroviral therapy are infected with viruses re-
sistant to at least one of the available antiretroviral drugs. More-
over, mutations conferring resistance to one drug may often
confer resistance to another drug. Furthermore, a significant pro-
portion of new HIV infections results from the transmission of
strains that are already resistant to one or more antiretroviral
drugs (33).
Here, we first tested ACV against HIV-1 variants that are resis-
tant to some of the most common anti-HIV NRTIs, zidovudine
(AZT) and lamivudine (3TC). We found that ACV efficiently sup-
pressed replication of NRTI-resistant viruses. However, while
ACV suppressed replication of AZT-resistant HIV-1 as efficiently
as it suppressed the wild-type variant, 3TC resistance, conferred
by the M184V mutation, decreased by 4-fold the susceptibility
to ACV.
Second, to further evaluate the ACV susceptibility of NRTI-
resistant HIV-1 variants, we tested a panel of six prototypical in-
fectious multidrug-resistant HIV-1 RT molecular clones. Each of
the clones carries several mutations that occur most frequently in
HIV-infected individuals treated with NRTIs. ACV (30 M) sup-
pressed equally well the replication of the six multidrug-resistant
clones and of HIV-1LAI.04. However, 3 M ACV (the EC50 for
HIV-1LAI.04) suppressed by 50% the replication of only four of the
six multidrug-resistant clones, indicating that some combinations
of the common NRTI mutations may provide a reduced suscep-
tibility to low-dose ACV. Finally, none of the tested viruses (ex-
cept an HIV-1 variant that carries a K65R RT mutation, which
showed an 2-fold decrease in susceptibility to 30 M ACV),
including one virus carrying the V75I RT mutation, were found to
be resistant to ACV. It was reported earlier that this mutation was
selected under the pressure of ACV or its prodrug derivative in single-
cell cultures of CD4	 lymphoblasts and the MT-4 cell line (25, 39).
However, in ex vivo tissues V75I-mutated virus was not resistant to
ACV. Also, in vivoACV does not select for this mutation (2, 19). This
further underscores the necessity to evaluate viral resistance in ex vivo
tissues, which represent the situation in vivo more adequately than
single-cell cultures. Nevertheless, it would be of interest to investigate
which particular features determine the difference between tissues
and single-cell cultures in viral resistance.
In resource-limited countries, the WHO recommends a first-
line regimen of two NRTIs and one NNRTI. Zidovudine and teno-
fovir disoproxil fumarate are the preferred NRTIs in this regimen
in combination with lamivudine or emtricitabine, while the
NNRTI is often nevirapine. Currently, inhibitors of viral protease,
integrase, or fusion are also important components of anti-HIV
cocktails (37). Although cross-resistance generally occurs pre-
dominantly between different drugs of the same class, we tested
ACV susceptibility to two protease inhibitors and to one fusion
inhibitor in HIV-1 variants resistant to nevirapine. We found that
these four resistant HIV-1 isolates were as susceptible to ACV as
the wild-type reference laboratory isolate HIV-1LAI.04.
Finally, understanding of the molecular mechanism of ACV
suppression of HIV-1 allowed us to potentiate its suppressive ac-
tivity. Indeed, our earlier data demonstrated that termination of
HIV-1 DNA elongation results from the incorporation of
ACV-TP by HIV-1 RT into the nascent DNA chain instead of its
natural counterpart dGTP (21). Therefore, increasing the intra-
cellular ACV-TP/dGTP ratio should increase the probability for
RT to incorporate ACV-TP rather than dGTP. This was previously
demonstrated in a cell-free system where a 12-fold decrease in the
concentration of dGTP resulted in an30% increase in ACV-TP
inhibition of HIV-1 RT (21). In the present work, we used ribavi-
rin to decrease the intracellular dGTP concentration and therefore
increase the intracellular ACV-TP/dGTP ratio. Ribavirin inhibits
IMP dehydrogenase, the enzyme that converts IMP to XMP, a key
step in the de novo biosynthesis of GTP and dGTP (8, 35). This
strategy was used earlier to potentiate the antiviral activity of ACV,
as well as those of ganciclovir and penciclovir, against herpesvirus
and hepatitis B virus (8, 28, 44) and also of 2=,3=-dideoxyinosine
(ddI) and 2=,3=-dideoxy-2,6-diaminopurine riboside (ddDAPR)
against HIV (4, 5).
Here, we used ribavirin at 10M, a concentration which per se
has no significant effect on HIV replication, and found that riba-
virin significantly potentiated the anti-HIV-1 activity of ACV. The
ribavirin-mediated potentiation of the ACV anti-HIV activity did
not seem to be related to the efficiency of ACV phosphorylation.
Indeed, a pronounced potentiation of the anti-HIV activity of
ACV by ribavirin was observed both for ACV and for prephospho-
rylated ACV prodrug derivatives (ACV ProTides). Although both
these strategies are based on the assumption that ribavirin acts by
decreasing the dGTP pool, other effects of ribavirin cannot be ex-
cluded. For example, ribavirin’s carboxamide group can make the
native nucleoside drug resemble adenosine or guanosine, which
therefore can be directly incorporated into DNA. Also, ribavirin is
known to modulate host T-cell-mediated immunity against viral in-
fection. Nevertheless, we think that the decrease of dGTP is the main
mechanism by which ribavirin potentiates ACV anti-HIV activity.
The difference between ex vivo tissues and isolated cells in potentiat-
ing these effects may be related to the size of the natural pool of dGTP.
It is likely that this pool is larger in highly proliferating immortalized
cell lines like MT-4 than in tissue cells.
In general, the fact that a drug that reduces the dGTP pool
potentiates the anti-HIV activity of ACV emphasizes that
ACV-TP and its natural counterpart dGTP compete for incorpo-
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ration during DNA elongation by HIV-1 RT and confirms once
again the existence of a direct effect of the activated ACV metab-
olite on HIV-1 RT.
The strategy of potentiating ACV anti-HIV activity may be
clinically relevant, as the concentration of 10 M ribavirin re-
quired for potentiation in our experiments is attained in human
plasma upon oral dosing of ribavirin in HCV-infected patients
(15). Our finding that ribavirin, an HCV drug, potentiates acyclo-
vir, an anti-HSV drug recently reported to have anti-HIV-1 activ-
ity, is important in light of frequent coinfection with these three
viruses: about 50% of HIV-1-infected patients are coinfected with
HSV-2 in the United States (29), and about one quarter of the
people infected with HIV are also infected with HCV (40). Our
results show that in combination with ACV, ribavirin could have a
dual-targeted action in coinfected individuals by inhibiting both
HCV and HIV-1. Although both drugs are already used for ther-
apy, only further studies may show whether this strategy could be
pursued in vivo.
In summary, we found that in human lymphoid tissue, ACV
suppresses the replication of HIV-1 of different clades and of dif-
ferent coreceptor tropisms as well as HIV-1 variants with muta-
tions conferring resistance to the currently used NRTIs, NNRTIs,
and inhibitors of viral protease, integrase, and fusion. Together
with the reported absence of emergence of HIV variants resistant
to ACV in vivo (2, 19) and the well-documented beneficial effect of
ACV on disease progression (20), these data warrant further clin-
ical investigation of the use of ACV alone or in combination with
anti-HIV drugs against this virus. Moreover, this inexpensive and
safe drug may be used to slow disease progression and delay
HAART in low-income countries where access to HAART is lim-
ited. The combination of ACV with ribavirin may be envisioned
also in topical microbicide applications where both HSV-2 and
HIV-1 might be suppressed with this drug combination regimen.
Further studies are needed to address the feasibility, the potential
benefits, and the cost-effectiveness of novel anti-HIV-1 strategies
based on ACV and its derivatives.
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